Company intelligence / Profile preview

The Column Group

San Francisco, California, United Statesthecolumngroup.com ↗

Ownership: Private
Development stage: Other

Overview

The Column Group is a leading venture capital firm focused on building and investing in early-stage biotechnology and life sciences companies. It has supported the formation and growth of over 55 biotech startups, with 18 successful exits generating $4 billion in returns. Its unique “edge-to-edge” investment model supports scientific innovation from inception to exit across multiple therapeutic areas via both platform technologies and single asset strategies.

Modalities: Small moleculeMonoclonal antibodyAntibody-drug conjugateProtein
Industry: Investors

Drug pipeline

2 assets

WELIREG

Commercial

Indications: VHL disease, Cancer

1 more asset in the full pipeline.

Request access →

Beyond the preview

Go deeper on The Column Group.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on The Column Group.

Explore the full profile